Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies

[1]  A. Lambeir,et al.  Metal ions shape α-synuclein , 2020, Scientific Reports.

[2]  D. Richardson,et al.  The anti-tumor agent, Dp44mT, promotes nuclear translocation of TFEB via inhibition of the AMPK-MTORC1 axis. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[3]  R. Chung,et al.  Extracellular Alpha-Synuclein Promotes a Neuroinhibitory Secretory Phenotype in Astrocytes , 2020, Life.

[4]  C. Cahill,et al.  Iron-responsive-like elements and neurodegenerative ferroptosis , 2020, Learning & memory.

[5]  I. Yanatori,et al.  The new role of poly (rC)-binding proteins as Iron transport chaperones: Proteins that could couple with inter-organelle interactions to safely traffic iron. , 2020, Biochimica et biophysica acta. General subjects.

[6]  D. Richardson,et al.  Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[7]  I. Yanatori,et al.  Ferroptosis at the crossroads of infection, aging and cancer , 2020, Cancer science.

[8]  F. Salachas,et al.  Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis , 2020, Journal of Neural Transmission.

[9]  Walter N. Moss,et al.  Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA , 2020, Proceedings of the National Academy of Sciences.

[10]  D. Richardson,et al.  Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[11]  S. Egan,et al.  Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD+/NADH ratios , 2020, British journal of pharmacology.

[12]  T. Niki,et al.  DJ-1-binding compound B enhances Nrf2 activity through the PI3-kinase-Akt pathway by DJ-1-dependent inactivation of PTEN , 2019, Brain Research.

[13]  I. Yanatori,et al.  How iron is handled in the course of heme catabolism: Integration of heme oxygenase with intracellular iron transport mechanisms mediated by poly (rC)-binding protein-2. , 2019, Archives of biochemistry and biophysics.

[14]  R. Olsthoorn,et al.  Relevance of the iron-responsive element (IRE) pseudotriloop structure for IRP1/2 binding and validation of IRE-like structures using the yeast three-hybrid system. , 2019, Gene.

[15]  A. Vashisht,et al.  A PCBP1–BolA2 chaperone complex delivers iron for cytosolic [2Fe–2S] cluster assembly , 2019, Nature Chemical Biology.

[16]  Haiyan Zhang,et al.  Identification of a New α-Synuclein Aggregation Inhibitor via Mass Spectrometry-based Screening. , 2019, ACS chemical neuroscience.

[17]  T. Hofer,et al.  Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification. , 2019, Journal of inorganic biochemistry.

[18]  V. Zinchenko,et al.  Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease , 2019, Journal of Bioenergetics and Biomembranes.

[19]  Alessandro Arcovito,et al.  Cryo-EM structure of the human ferritin–transferrin receptor 1 complex , 2019, Nature Communications.

[20]  M. Knutson.  Non-transferrin-bound iron transporters. , 2019, Free radical biology & medicine.

[21]  I. Yanatori,et al.  DMT1 and iron transport , 2019, Free radical biology & medicine.

[22]  H. Kawabata.  Transferrin and transferrin receptors update , 2019, Free radical biology & medicine.

[23]  B. Gallie,et al.  Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox , 2019, PloS one.

[24]  J. Morales-Garcia,et al.  Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease , 2019, International journal of molecular sciences.

[25]  M. Goulding,et al.  Switching on Endogenous Metal Binding Proteins in Parkinson’s Disease , 2019, Cells.

[26]  Donna D. Zhang,et al.  NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis , 2019, Redox biology.

[27]  M. Marinelli.  Dopamine , 2018, Reactions Weekly.

[28]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[29]  J. Mancias,et al.  The Role of NCOA4-Mediated Ferritinophagy in Health and Disease , 2018, Pharmaceuticals.

[30]  M. Youdim.  Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases , 2018, Journal of Neural Transmission.

[31]  L. Ruiz,et al.  The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis , 2018, Cells.

[32]  A. Zeidan,et al.  To chelate or not to chelate in MDS: That is the question! , 2018, Blood reviews.

[33]  Yoshiro Saito,et al.  Distribution of oxidized DJ-1 in Parkinson’s disease-related sites in the brain and in the peripheral tissues: effects of aging and a neurotoxin , 2018, Scientific Reports.

[34]  R. Liddle.  Parkinson’s disease from the gut , 2018, Brain Research.

[35]  S. Ballas,et al.  The effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review , 2018, American journal of hematology.

[36]  H. Lodish,et al.  Critical Issues in Diamond-Blackfan Anemia and Prospects for Novel Treatment. , 2018, Hematology/oncology clinics of North America.

[37]  S. Chirumbolo,et al.  Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. , 2018, Current medicinal chemistry.

[38]  N. Braidy,et al.  Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. , 2018, Dalton transactions.

[39]  Carolyn M. Sue,et al.  Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives , 2018, Current Neurology and Neuroscience Reports.

[40]  P. Pagliaro,et al.  Redox Aspects of Chaperones in Cardiac Function , 2018, Front. Physiol..

[41]  M. Sitti,et al.  Redox metals homeostasis in multiple sclerosis and amyotrophic lateral sclerosis: a review , 2018, Cell Death & Disease.

[42]  Junxia Xie,et al.  New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson’s Disease , 2018, Front. Mol. Neurosci..

[43]  L. Defebvre,et al.  Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? , 2017, Antioxidants & redox signaling.

[44]  T. Claudepierre,et al.  Cellular and Molecular Aspects of the β-N-Methylamino-l-alanine (BMAA) Mode of Action within the Neurodegenerative Pathway: Facts and Controversy , 2017, Toxins.

[45]  Simon C Watkins,et al.  PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals , 2017, Cell.

[46]  Neena Singh,et al.  α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson’s disease , 2017, Scientific Reports.

[47]  W. Gu,et al.  NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. , 2017, Molecular cell.

[48]  J. Andersen,et al.  A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo , 2017, Neuropharmacology.

[49]  Tadeusz Sarna,et al.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease , 2017, Progress in Neurobiology.

[50]  Megan Lee,et al.  Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review , 2017, PloS one.

[51]  David M. Shackleford,et al.  The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease , 2017, Acta neuropathologica communications.

[52]  I. Yanatori,et al.  The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer , 2017, The Journal of Biological Chemistry.

[53]  Yukio Nakamura,et al.  A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2. , 2017, Blood advances.

[54]  R. Nussbaum,et al.  α-Synuclein in gut endocrine cells and its implications for Parkinson's disease. , 2017, JCI insight.

[55]  Qiangqiang Liu,et al.  New tris(dopamine) derivative as an iron chelator. Synthesis, solution thermodynamic stability, and antioxidant research. , 2017, Journal of inorganic biochemistry.

[56]  P. Whitley,et al.  Steady-State Kinetics of α-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species. , 2017, Biochemistry.

[57]  Maneesh C. Patel,et al.  Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease , 2017, Scientific Reports.

[58]  D. Yanagisawa,et al.  Mitochondrial ferritin protects SH-SY5Y cells against H2O2-induced oxidative stress and modulates α-synuclein expression , 2017, Experimental Neurology.

[59]  Scott J. Dixon,et al.  Ferroptosis: bug or feature? , 2017, Immunological reviews.

[60]  C. Philpott,et al.  PCBP1 and NCOA4 regulate erythroid iron storage and heme biosynthesis , 2017, The Journal of clinical investigation.

[61]  D. Wink,et al.  Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1. , 2017, Biochimica et biophysica acta. General subjects.

[62]  N. Rouach,et al.  Human astrocytes: structure and functions in the healthy brain , 2017, Brain Structure and Function.

[63]  G. Mellick,et al.  Role of the VPS35 D620N mutation in Parkinson's disease. , 2017, Parkinsonism & related disorders.

[64]  C. Achat-Mendes,et al.  Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator , 2017, Neural regeneration research.

[65]  P. Lingor,et al.  Alpha-synuclein and iron: two keys unlocking Parkinson’s disease , 2017, Journal of Neural Transmission.

[66]  M. Reith,et al.  A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease. , 2017, ACS chemical neuroscience.

[67]  A. Mason,et al.  Erythroid cell mitochondria receive endosomal iron by a "kiss-and-run" mechanism. , 2016, Biochimica et biophysica acta.

[68]  D. Richardson,et al.  The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells. , 2016, Biochimica et biophysica acta.

[69]  D. Richardson,et al.  A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity* , 2016, The Journal of Biological Chemistry.

[70]  A. Mason,et al.  Endosome–mitochondria interactions are modulated by iron release from transferrin , 2016, The Journal of cell biology.

[71]  Ferdinand Schweser,et al.  Quantitative Susceptibility Mapping in Parkinson's Disease , 2016, PloS one.

[72]  Neena Singh,et al.  Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease. , 2016, Free radical biology & medicine.

[73]  K. Chaudhuri,et al.  New concepts in the pathogenesis and presentation of Parkinson's disease. , 2016, Clinical medicine.

[74]  O. Schueler‐Furman,et al.  Parkin Somatic Mutations Link Melanoma and Parkinson's Disease. , 2016, Journal of genetics and genomics = Yi chuan xue bao.

[75]  I. Yanatori,et al.  Iron Export through the Transporter Ferroportin 1 Is Modulated by the Iron Chaperone PCBP2* , 2016, The Journal of Biological Chemistry.

[76]  D. Richardson,et al.  Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase. , 2016, Biochemical pharmacology.

[77]  Wen-Chang Chang,et al.  Paraquat Induces Cell Death Through Impairing Mitochondrial Membrane Permeability , 2016, Molecular Neurobiology.

[78]  S. Dixon,et al.  Mechanisms of ferroptosis , 2016, Cellular and Molecular Life Sciences.

[79]  Yonatan Stelzer,et al.  Parkinson-associated risk variant in enhancer element produces subtle effect on target gene expression , 2016, Nature.

[80]  R. Ortega,et al.  α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons , 2016, Molecular Neurobiology.

[81]  G. Kontoghiorghes,et al.  New developments and controversies in iron metabolism and iron chelation therapy. , 2016, World journal of methodology.

[82]  Xiao-Xing Li,et al.  Rab1 in Cell Signaling, Cancer and Other Diseases , 2016, Oncogene.

[83]  Dipendra K. Aryal,et al.  Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice , 2016, Proceedings of the National Academy of Sciences.

[84]  M. Castro,et al.  Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders , 2015, International journal of molecular sciences.

[85]  S. Biswas,et al.  The regulation of p53 up‐regulated modulator of apoptosis by JNK/c‐Jun pathway in β‐amyloid‐induced neuron death , 2015, Journal of neurochemistry.

[86]  A. Bush,et al.  Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse , 2015, Neurobiology of Disease.

[87]  M. Núñez,et al.  The novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death. , 2015, Biochemical and biophysical research communications.

[88]  Suneil K. Kalia,et al.  α-Synuclein and Lewy pathology in Parkinson's disease. , 2015, Current opinion in neurology.

[89]  H. Lashuel,et al.  Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis. , 2015, Journal of the American Chemical Society.

[90]  M. Sharon,et al.  The Parkinson’s-associated protein DJ-1 regulates the 20S proteasome , 2015, Nature Communications.

[91]  Richard Wade-Martins,et al.  Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.

[92]  D. Richardson,et al.  Duodenal Cytochrome b (DCYTB) in Iron Metabolism: An Update on Function and Regulation , 2015, Nutrients.

[93]  P. Spano,et al.  Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? , 2015, Parkinson's disease.

[94]  W. Gu,et al.  Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.

[95]  P. Lingor,et al.  Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease. , 2015, Metallomics : integrated biometal science.

[96]  J. Vickers,et al.  The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to α-synuclein inclusions , 2015, Molecular and Cellular Neuroscience.

[97]  N. Calakos,et al.  Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. , 2015, The Journal of clinical investigation.

[98]  R. Youle,et al.  The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease , 2015, Neuron.

[99]  G. Petsko,et al.  Transnitrosylation from DJ-1 to PTEN Attenuates Neuronal Cell Death in Parkinson's Disease Models , 2014, The Journal of Neuroscience.

[100]  Jonghan Kim,et al.  Iron and mechanisms of emotional behavior. , 2014, The Journal of nutritional biochemistry.

[101]  S. Goswami,et al.  SG2NA recruits DJ-1 and Akt into the mitochondria and membrane to protect cells from oxidative damage. , 2014, Free radical biology & medicine.

[102]  D. Richardson,et al.  Glutathione S-transferase and MRP1 form an integrated system involved in the storage and transport of dinitrosyl-dithiolato iron complexes in cells. , 2014, Free radical biology & medicine.

[103]  D. Richardson,et al.  The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! , 2014, Free radical biology & medicine.

[104]  I. Yanatori,et al.  Chaperone protein involved in transmembrane transport of iron. , 2014, The Biochemical journal.

[105]  M. Marsella,et al.  Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. , 2014, Hematology/oncology clinics of North America.

[106]  Neena Singh,et al.  Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. , 2014, Antioxidants & redox signaling.

[107]  DuhamelAlain,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .

[108]  M. O’Banion,et al.  Neuroinflammation and M2 microglia: the good, the bad, and the inflamed , 2014, Journal of Neuroinflammation.

[109]  F. Wang,et al.  Role and Mechanism of Microglial Activation in Iron-Induced Selective and Progressive Dopaminergic Neurodegeneration , 2014, Molecular Neurobiology.

[110]  S. Rivella,et al.  IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.

[111]  Blaine R. Roberts,et al.  An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta , 2014 .

[112]  K. Tsumoto,et al.  Thermodynamic and structural characterization of the specific binding of Zn(II) to human protein DJ-1. , 2014, Biochemistry.

[113]  S. Gygi,et al.  Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy , 2014, Nature.

[114]  L. Bubacco,et al.  DJ-1 Is a Copper Chaperone Acting on SOD1 Activation* , 2014, The Journal of Biological Chemistry.

[115]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[116]  Eberhard O Voit,et al.  Rotenone and paraquat perturb dopamine metabolism: A computational analysis of pesticide toxicity. , 2014, Toxicology.

[117]  A. Munnich,et al.  Regional siderosis: a new challenge for iron chelation therapy , 2013, Front. Pharmacol..

[118]  R. Edwards,et al.  The Function of α-Synuclein , 2013, Neuron.

[119]  Ke Xu,et al.  Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients. , 2013, Magnetic resonance imaging.

[120]  S. Mandel,et al.  Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. , 2013, Free radical biology & medicine.

[121]  F. Codazzi,et al.  Iron uptake in quiescent and inflammation-activated astrocytes: A potentially neuroprotective control of iron burden , 2013, Biochimica et biophysica acta.

[122]  M. Sari,et al.  Hepcidin Bound to α2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels , 2013, The Journal of Biological Chemistry.

[123]  X. Xu,et al.  Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytotoxicity* , 2013, The Journal of Biological Chemistry.

[124]  D. Richardson,et al.  Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. , 2013, Biochimica et biophysica acta.

[125]  P. Subramanian,et al.  Each Member of the Poly-r(C)-binding Protein 1 (PCBP) Family Exhibits Iron Chaperone Activity toward Ferritin* , 2013, The Journal of Biological Chemistry.

[126]  Hitoshi Takahashi,et al.  The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders , 2013, Molecular Neurobiology.

[127]  J. Bonny,et al.  Is R2* a New MRI Biomarker for the Progression of Parkinson’s Disease? A Longitudinal Follow-Up , 2013, PloS one.

[128]  K. Nakao,et al.  Secreted protein lipocalin‐2 promotes microglial M1 polarization , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[129]  D. Hinkle,et al.  DJ-1 Expression Modulates Astrocyte-Mediated Protection Against Neuronal Oxidative Stress , 2013, Journal of Molecular Neuroscience.

[130]  P. Buehler,et al.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. , 2013, Blood.

[131]  P. Bradford,et al.  L-Arginine and Nitric Oxide in CNS Function and Neurodegenerative Diseases , 2013, Critical reviews in food science and nutrition.

[132]  Lucía Gutiérrez,et al.  Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia , 2012, Proceedings of the National Academy of Sciences.

[133]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[134]  R. Eisenstein,et al.  Mammalian iron metabolism and its control by iron regulatory proteins. , 2012, Biochimica et biophysica acta.

[135]  F. Loreni,et al.  &agr;-Synuclein expression is modulated at the translational level by iron , 2012, Neuroreport.

[136]  Peter Teismann,et al.  Chelators in the Treatment of Iron Accumulation in Parkinson's Disease , 2012, International journal of cell biology.

[137]  N. Greig,et al.  The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5′Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression , 2012, Parkinson's disease.

[138]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[139]  S. David,et al.  Iron Efflux from Astrocytes Plays a Role in Remyelination , 2012, The Journal of Neuroscience.

[140]  M. Kotze,et al.  The conundrum of iron in multiple sclerosis – time for an individualised approach , 2012, Metabolic Brain Disease.

[141]  J. Connor,et al.  Functional roles of transferrin in the brain. , 2012, Biochimica et biophysica acta.

[142]  T. Mak,et al.  Consequences of DJ-1 upregulation following p53 loss and cell transformation , 2012, Oncogene.

[143]  S. Cha,et al.  YajL, Prokaryotic Homolog of Parkinsonism-associated Protein DJ-1, Functions as a Covalent Chaperone for Thiol Proteome* , 2011, The Journal of Biological Chemistry.

[144]  D. Richardson,et al.  Nitric Oxide Storage and Transport in Cells Are Mediated by Glutathione S-Transferase P1-1 and Multidrug Resistance Protein 1 via Dinitrosyl Iron Complexes* , 2011, The Journal of Biological Chemistry.

[145]  S. Bruley des Varannes,et al.  Parkinson disease , 2011, Neurology.

[146]  G. Semenza,et al.  Hypoxia‐inducible factor 1 mediates increased expression of NADPH oxidase‐2 in response to intermittent hypoxia , 2011, Journal of cellular physiology.

[147]  Jason R. Hickok,et al.  Dinitrosyliron complexes are the most abundant nitric oxide-derived cellular adduct: biological parameters of assembly and disappearance. , 2011, Free radical biology & medicine.

[148]  M. Farrer,et al.  VPS35 mutations in Parkinson disease. , 2011, American journal of human genetics.

[149]  D. Dickson,et al.  Neuropathology underlying clinical variability in patients with synucleinopathies , 2011, Acta Neuropathologica.

[150]  M. Wilson.  The role of cysteine oxidation in DJ-1 function and dysfunction. , 2011, Antioxidants & redox signaling.

[151]  D. Richardson,et al.  The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity , 2011, Molecular Pharmacology.

[152]  H. Adami,et al.  Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.

[153]  R. Armstrong,et al.  Visual Symptoms in Parkinson's Disease , 2011, Parkinson's disease.

[154]  D. Maraganore.  Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease , 2011, Journal of movement disorders.

[155]  S. Daubner,et al.  Tyrosine hydroxylase and regulation of dopamine synthesis. , 2011, Archives of biochemistry and biophysics.

[156]  G. Semenza,et al.  Hypoxia‐Inducible Factor 1 Mediates Increased Expression of NADPH Oxidase‐2 in Response to Intermittent Hypoxia , 2011 .

[157]  S. Robinson,et al.  Accumulation of Non-Transferrin-Bound Iron by Neurons, Astrocytes, and Microglia , 2011, Neurotoxicity Research.

[158]  T. Tweed.  Space , 2011, STEM Education in the Primary School.

[159]  Junxia Xie,et al.  Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells , 2011, Journal of Neural Transmission.

[160]  S. Aquilonius,et al.  Manganese-Induced Parkinsonism due to Ephedrone Abuse , 2011, Parkinson's disease.

[161]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[162]  T. Iancu.  Ultrastructural aspects of iron storage, transport and metabolism , 2011, Journal of Neural Transmission.

[163]  P. Brundin,et al.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.

[164]  L. Della Corte,et al.  Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration , 2011, Journal of Neural Transmission.

[165]  David R. Brown,et al.  Correction: Alpha-Synuclein Is a Cellular Ferrireductase , 2011, PLoS ONE.

[166]  Philip L De Jager,et al.  Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.

[167]  A. Manning-Boğ,et al.  Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain , 2011, Molecular Neurodegeneration.

[168]  N. Greig,et al.  The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen , 2011, Journal of Neural Transmission.

[169]  S. Cragg,et al.  α-Synuclein and dopamine at the crossroads of Parkinson's disease , 2010, Trends in Neurosciences.

[170]  Paul T. Schumacker,et al.  Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 , 2010, Nature.

[171]  Xudong Huang,et al.  Selective Translational Control of the Alzheimer Amyloid Precursor Protein Transcript by Iron Regulatory Protein-1*♦ , 2010, The Journal of Biological Chemistry.

[172]  L. Chin,et al.  Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. , 2010, Human molecular genetics.

[173]  S. Robinson,et al.  Synergistic accumulation of iron and zinc by cultured astrocytes , 2010, Journal of Neural Transmission.

[174]  M. Farrer,et al.  Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.

[175]  D. Richardson,et al.  Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol , 2010, Proceedings of the National Academy of Sciences.

[176]  Beat Meier,et al.  Prions , 2010 .

[177]  D. Richardson,et al.  The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich’s ataxia , 2010, Journal of Molecular Medicine.

[178]  Alzheimer’s Association.  2010 Alzheimer's disease facts and figures , 2010, Alzheimer's & Dementia.

[179]  W. Seaman,et al.  Binding and uptake of H-ferritin are mediated by human transferrin receptor-1 , 2010, Proceedings of the National Academy of Sciences.

[180]  S. Murayama,et al.  α-SYNUCLEIN ACCUMULATION IN SKIN NERVE FIBERS REVEALED BY SKIN BIOPSY IN PURE AUTONOMIC FAILURE , 2010, Neurology.

[181]  Junxia Xie,et al.  Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent , 2010, Cell Research.

[182]  郑莉,et al.  HePcidin的临床研究进展 , 2010 .

[183]  Junxia Xie,et al.  Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. , 2010, Free radical biology & medicine.

[184]  E. Masliah,et al.  Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies* , 2010, The Journal of Biological Chemistry.

[185]  P. Brundin,et al.  Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[186]  D. Dickson,et al.  Neuropathology of non-motor features of Parkinson disease. , 2009, Parkinsonism & related disorders.

[187]  E. Wolters.  Non-motor extranigral signs and symptoms in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[188]  David N. Powers,et al.  Control of Iron Homeostasis by an Iron-Regulated Ubiquitin Ligase , 2009, Science.

[189]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[190]  D. Richardson,et al.  Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant , 2009, Proceedings of the National Academy of Sciences.

[191]  Hong Jiang,et al.  Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 cells , 2009, Neurobiology of Aging.

[192]  M. Beal,et al.  Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity , 2009, The Journal of Biological Chemistry.

[193]  C. Colton.  Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain , 2009, Journal of Neuroimmune Pharmacology.

[194]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[195]  S. Prusiner,et al.  Is Parkinson's disease a prion disorder? , 2009, Proceedings of the National Academy of Sciences.

[196]  J. Im,et al.  Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.

[197]  D. Richardson,et al.  Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype. , 2009, Biochimica et biophysica acta.

[198]  R. Petersen,et al.  Prion Protein (PrP) Knock-Out Mice Show Altered Iron Metabolism: A Functional Role for PrP in Iron Uptake and Transport , 2009, PloS one.

[199]  P. Kuchel,et al.  Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. , 2009, Blood.

[200]  J. Trojanowski,et al.  A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease , 2009, Neurobiology of Disease.

[201]  Xiaomin Su,et al.  Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity , 2009, Neurotoxicity Research.

[202]  B. Todorich,et al.  Oligodendrocytes and myelination: The role of iron , 2009, Glia.

[203]  Mark A. Wilson,et al.  Formation of a Stabilized Cysteine Sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ-1* , 2009, Journal of Biological Chemistry.

[204]  N. Greig,et al.  Physiological and Pathological Role of Alpha-synuclein in Parkinson’s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element , 2009, International journal of molecular sciences.

[205]  F. Othman,et al.  An anticancer agent , 2009 .

[206]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[207]  D. Selkoe,et al.  α‐Synuclein and Polyunsaturated Fatty Acids Promote Clathrin‐Mediated Endocytosis and Synaptic Vesicle Recycling , 2009, Traffic.

[208]  F. Fujiyama,et al.  Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.

[209]  J. Stankiewicz,et al.  Role of iron in neurotoxicity: a cause for concern in the elderly? , 2009, Current opinion in clinical nutrition and metabolic care.

[210]  T. Dawson,et al.  What causes cell death in Parkinson's disease? , 2008, Annals of neurology.

[211]  J. Beard,et al.  Dopamine D2 receptor expression is altered by changes in cellular iron levels in PC12 cells and rat brain tissue. , 2008, The Journal of nutrition.

[212]  B. Todorich,et al.  Tim‐2 is the receptor for H‐ferritin on oligodendrocytes , 2008, Journal of neurochemistry.

[213]  N. Cole.  Metal catalyzed oxidation of alpha-synuclein--a role for oligomerization in pathology? , 2008, Current Alzheimer research.

[214]  Charles Duyckaerts,et al.  Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[215]  Sharad Kumar,et al.  Regulation of the divalent metal ion transporter DMT1 and iron homeostasis by a ubiquitin-dependent mechanism involving Ndfips and WWP2. , 2008, Blood.

[216]  N. Turro,et al.  New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals , 2008, Proceedings of the National Academy of Sciences.

[217]  Martyn N J Paley,et al.  MRI assessment of basal ganglia iron deposition in Parkinson's disease , 2008, Journal of magnetic resonance imaging : JMRI.

[218]  T. Iwatsubo,et al.  Lewy Body Pathology Involves Cutaneous Nerves , 2008, Journal of neuropathology and experimental neurology.

[219]  Yong Tong,et al.  Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease. , 2008, Current bioactive compounds.

[220]  Tianhong Pan,et al.  The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. , 2008, Brain : a journal of neurology.

[221]  Ming Zhan,et al.  RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways , 2008, Proceedings of the National Academy of Sciences.

[222]  D. Richardson,et al.  The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation , 2008, Proceedings of the National Academy of Sciences.

[223]  D. Sulzer,et al.  Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease , 2008, Journal of neurochemistry.

[224]  T. Stemmler,et al.  A Cytosolic Iron Chaperone That Delivers Iron to Ferritin , 2008, Science.

[225]  D. Berg,et al.  Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[226]  R. Perez,et al.  α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice , 2008, Neuroscience Letters.

[227]  P. Chan,et al.  Silencing α-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells , 2008, Neurochemical Research.

[228]  P. Vieregge.  [Idiopathic Parkinson's disease]. , 2008, Fortschritte der Neurologie-Psychiatrie.

[229]  A. Schapira.  Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[230]  N. Gao,et al.  Effect of α-synuclein on the promoter activity of tyrosine hydroxylase gene , 2007, Neuroscience Bulletin.

[231]  J. Jankovic,et al.  Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[232]  E. Morgan,et al.  Iron trafficking inside the brain , 2007, Journal of neurochemistry.

[233]  D. Richardson,et al.  Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. , 2007, Carcinogenesis.

[234]  D. Richardson,et al.  The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark – from iron metabolism to tumorigenesis , 2007, Oncogene.

[235]  T. Dawson,et al.  DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.

[236]  D. Richardson,et al.  Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. , 2007, Dalton transactions.

[237]  Bharathi,et al.  Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. , 2007, Biochemical and biophysical research communications.

[238]  D. Richardson,et al.  Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. , 2007, Blood.

[239]  F. Sanvito,et al.  Mitochondrial Ferritin Expression in Adult Mouse Tissues , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[240]  Nathalie Boddaert,et al.  Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.

[241]  F. Vallelian,et al.  CD163‐expressing monocytes constitute an endotoxin‐sensitive Hb clearance compartment within the vascular system , 2007, Journal of leukocyte biology.

[242]  S. Robinson,et al.  The Pivotal Role of Astrocytes in the Metabolism of Iron in the Brain , 2007, Neurochemical Research.

[243]  Ritwik Ghosh,et al.  DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. , 2007, Cancer research.

[244]  J. Schulz,et al.  Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[245]  K. Beyer.  Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane , 2007, Cell Biochemistry and Biophysics.

[246]  Mayka Sanchez,et al.  Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency , 2007, Nature Structural &Molecular Biology.

[247]  W. Geldenhuys,et al.  Voltage-gated Calcium Channels Provide an Alternate Route for Iron Uptake in Neuronal Cell Cultures , 2007, Neurochemical Research.

[248]  R. Tanzi,et al.  The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.

[249]  D. Richardson,et al.  Iron uptake and metabolism in the new millennium. , 2007, Trends in cell biology.

[250]  J. Wickens,et al.  Space, time and dopamine , 2007, Trends in Neurosciences.

[251]  P. Várnai,et al.  Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels , 2006, The Journal of cell biology.

[252]  M. Akabas,et al.  Identification of an Intestinal Folate Transporter and the Molecular Basis for Hereditary Folate Malabsorption , 2006, Cell.

[253]  Claire M. Brown,et al.  Direct interorganellar transfer of iron from endosome to mitochondrion. , 2006, Blood.

[254]  D. Richardson,et al.  The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. , 2006, Carcinogenesis.

[255]  M. Kurrer,et al.  Constitutive Endocytosis of CD163 Mediates Hemoglobin-Heme Uptake and Determines the Noninflammatory and Protective Transcriptional Response of Macrophages to Hemoglobin , 2006, Circulation research.

[256]  D. Rubinsztein,et al.  The roles of intracellular protein-degradation pathways in neurodegeneration , 2006, Nature.

[257]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[258]  J. Trojanowski,et al.  Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.

[259]  D. Richardson,et al.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.

[260]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[261]  K. Xia,et al.  Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.

[262]  D. Richardson,et al.  Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[263]  J. Xie,et al.  Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.

[264]  L. Zecca,et al.  Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability , 2006, Journal of Neural Transmission.

[265]  Louise K. Charkoudian,et al.  Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. , 2006, Inorganic chemistry.

[266]  D. Richardson,et al.  Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. , 2006, Blood.

[267]  간다 유타카,et al.  Anti-tumor agent , 2006 .

[268]  D. Richardson,et al.  The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer , 2005, Pharmacological Reviews.

[269]  G. Cha,et al.  Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. , 2005, Gene.

[270]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[271]  J. J. Sharp,et al.  Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells , 2005, Nature Genetics.

[272]  D. Berg,et al.  In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage , 2005, Movement disorders : official journal of the Movement Disorder Society.

[273]  C. Vulpe,et al.  Identification of an Intestinal Heme Transporter , 2005, Cell.

[274]  L. Stefanis,et al.  α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.

[275]  Reidun Torp,et al.  Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. , 2005, Human molecular genetics.

[276]  R. Barker,et al.  Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease , 2005, Neuroscience Letters.

[277]  David S. Park,et al.  Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[278]  David W. Miller,et al.  Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. , 2005, Brain research. Molecular brain research.

[279]  C. Griesinger,et al.  Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[280]  D. Richardson,et al.  Iron trafficking in the mitochondrion: novel pathways revealed by disease. , 2005, Blood.

[281]  J. Andersen,et al.  Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO‐mediated pathway not involving peroxynitrite: implications for Parkinson's disease , 2005, Journal of neurochemistry.

[282]  E. Beutler,et al.  Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. , 2005, Blood cells, molecules & diseases.

[283]  P. Calabresi,et al.  Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1 , 2005, Neuron.

[284]  P. Riederer,et al.  Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease , 2005, Progress in Neurobiology.

[285]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[286]  Alberto Albertini,et al.  The neuromelanin of human substantia nigra: physiological and pathogenic aspects. , 2004, Pigment cell research.

[287]  Guangjun Nie,et al.  Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. , 2004, Blood.

[288]  D. Richardson,et al.  The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. , 2004, Biochimica et biophysica acta.

[289]  D. Richardson,et al.  Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. , 2004, Blood.

[290]  P. Chan,et al.  Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells , 2004, Neuroscience Letters.

[291]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[292]  M. Edwards,et al.  Hereditary haemochromatosis is unlikely to cause movement disorders , 2004, Journal of Neurology.

[293]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[294]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[295]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[296]  T. Hastings,et al.  Could a loss of α‐synuclein function put dopaminergic neurons at risk? , 2004 .

[297]  J. Nutt,et al.  Parkinson's disease , 2004, The Lancet.

[298]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[299]  Tomoya Kinumi,et al.  Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. , 2004, Biochemical and biophysical research communications.

[300]  J. Joseph,et al.  α-Synuclein Up-regulation and Aggregation during MPP+-induced Apoptosis in Neuroblastoma Cells , 2004, Journal of Biological Chemistry.

[301]  V. Subramaniam,et al.  Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. , 2004, Journal of hepatology.

[302]  D. Koziorowski,et al.  Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. , 2004, Biochimica et biophysica acta.

[303]  D. Richardson.  Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions , 2004, Annals of the New York Academy of Sciences.

[304]  T. Araki,et al.  Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study , 2004, European Neuropsychopharmacology.

[305]  G. Perry,et al.  Oxidative Stress and Redox‐Active Iron in Alzheimer's Disease , 2004, Annals of the New York Academy of Sciences.

[306]  Keith D Wilkinson,et al.  Familial Parkinson's Disease-associated L166P Mutation Disrupts DJ-1 Protein Folding and Function* , 2004, Journal of Biological Chemistry.

[307]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[308]  T. Niki,et al.  DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.

[309]  M. Youdim,et al.  Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.

[310]  W. Jefferies,et al.  Identification of a Novel Route of Iron Transcytosis across the Mammalian Blood‐Brain Barrier , 2003, Microcirculation.

[311]  E. Morgan,et al.  The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain , 2003, Journal of neurochemistry.

[312]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[313]  D. Richardson,et al.  The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. , 2003, Carcinogenesis.

[314]  B. Oostra,et al.  DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.

[315]  Serge Gauthier,et al.  Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. , 2003, The Biochemical journal.

[316]  K. Jellinger,et al.  Neuropathological spectrum of synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.

[317]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[318]  S. David,et al.  Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.

[319]  G. Petsko,et al.  The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[320]  N. Baroukh,et al.  Myelination and motor coordination are increased in transferrin transgenic mice , 2003, Journal of neuroscience research.

[321]  D. Richardson,et al.  Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. , 2003, Carcinogenesis.

[322]  G. Fiskum,et al.  Mitochondrial Mechanisms of Neural Cell Death and Neuroprotective Interventions in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[323]  B. Bergamasco,et al.  Residual substantia nigra neuromelanin in Parkinson’s disease is cross-linked to α-synuclein , 2003, Neurochemistry International.

[324]  Z. Cabantchik,et al.  Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. , 2003, Blood.

[325]  David W. Miller,et al.  Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines , 2003, Journal of neurochemistry.

[326]  Sonya Cunningham,et al.  1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. , 2003, The Biochemical journal.

[327]  J. Beard,et al.  Neonatal iron deficiency results in irreversible changes in dopamine function in rats. , 2003, The Journal of nutrition.

[328]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[329]  Z. Harris.  Aceruloplasminemia , 2003, Journal of the Neurological Sciences.

[330]  H. Miyajima,et al.  Aceruloplasminemia, an inherited disorder of iron metabolism , 2003, Biometals.

[331]  M. Cazzola,et al.  Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. , 2003, Blood.

[332]  Sun-Young Lee,et al.  Lipid interaction of α‐synuclein during the metal‐catalyzed oxidation in the presence of Cu2+ and H2O2 , 2003, Journal of neurochemistry.

[333]  D. Richardson,et al.  Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. , 2003, The Biochemical journal.

[334]  Patrik Brundin,et al.  Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.

[335]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[336]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[337]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[338]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[339]  M. Hentze,et al.  Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: Implications for regulation and cellular function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[340]  P. Blumbergs,et al.  Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies. , 2002, The American journal of pathology.

[341]  T. Niki,et al.  DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. , 2002, Biological & pharmaceutical bulletin.

[342]  P. Gros,et al.  Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. , 2002, Kidney international.

[343]  D. Richardson,et al.  The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner. , 2002, European journal of biochemistry.

[344]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[345]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[346]  D. Richardson,et al.  The iron metabolism of neoplastic cells: alterations that facilitate proliferation? , 2002, Critical reviews in oncology/hematology.

[347]  Paul Alan Cox,et al.  Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. , 2002, Neurology.

[348]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[349]  Alberto Gatti,et al.  The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.

[350]  M. Hentze,et al.  Iron‐dependent regulation of the divalent metal ion transporter , 2001, FEBS letters.

[351]  D. Sulzer,et al.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.

[352]  Hiroyoshi Ariga,et al.  DJ-1 Positively Regulates the Androgen Receptor by Impairing the Binding of PIASxα to the Receptor* , 2001, The Journal of Biological Chemistry.

[353]  Jin Gao,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. , 2001, Blood.

[354]  J. Connor,et al.  Iron and iron management proteins in neurobiology. , 2001, Pediatric neurology.

[355]  J. Beard,et al.  Iron deficiency decreases dopamine D1 and D2 receptors in rat brain , 2001, Pharmacology Biochemistry and Behavior.

[356]  P. Arosio,et al.  A Human Mitochondrial Ferritin Encoded by an Intronless Gene* , 2001, The Journal of Biological Chemistry.

[357]  B. Carroll,et al.  Serum Melanotransferrin, p97 as a Biochemical Marker of Alzheimer's Disease , 2001, Neuropsychopharmacology.

[358]  J. Trojanowski,et al.  Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. , 2001, Parkinsonism & related disorders.

[359]  Cornelia M. van Duijn,et al.  A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis , 2001, Nature Genetics.

[360]  D. Richardson,et al.  Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. , 2001, Biochimica et biophysica acta.

[361]  D. Richardson.  The controversial role of deferiprone in the treatment of thalassemia. , 2001, The Journal of laboratory and clinical medicine.

[362]  J. Connor,et al.  A light and electron microscopic study of the iron transporter protein DMT-1 in the monkey cerebral neocortex and hippocampus , 2001, Journal of neurocytology.

[363]  Bruno Turlin,et al.  A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload* , 2001, The Journal of Biological Chemistry.

[364]  M Gallorini,et al.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.

[365]  D. Richardson,et al.  Nitrogen Monoxide (NO) and Glucose , 2001, The Journal of Biological Chemistry.

[366]  R J Simpson,et al.  An Iron-Regulated Ferric Reductase Associated with the Absorption of Dietary Iron , 2001, Science.

[367]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[368]  A. Mitsumoto,et al.  DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin , 2001, Free radical research.

[369]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[370]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[371]  P. Riederer,et al.  Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.

[372]  P. Lansbury,et al.  Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .

[373]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[374]  J. Beard,et al.  Iron deficiency alters dopamine transporter functioning in rat striatum. , 2000, The Journal of nutrition.

[375]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[376]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[377]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[378]  J. Tateishi,et al.  Subacute myelo‐optico‐neuropathy: Clioquinol intoxication in humans and animals , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[379]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[380]  S. Abboud,et al.  A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism* , 2000, The Journal of Biological Chemistry.

[381]  Hiroshi Kawabata,et al.  Transferrin Receptor 2-α Supports Cell Growth Both in Iron-chelated Cultured Cells and in Vivo * , 2000, The Journal of Biological Chemistry.

[382]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[383]  J O Rinne,et al.  Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.

[384]  D. Richardson,et al.  Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells. , 2000, Biochemistry.

[385]  D. Richardson.  The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. , 2000, European journal of biochemistry.

[386]  A. Brownlie,et al.  Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter , 2000, Nature.

[387]  S. David,et al.  Alternative RNA Splicing Generates a Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin in Mammalian Brain* , 2000, The Journal of Biological Chemistry.

[388]  E. Morgan,et al.  Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.

[389]  R J Simpson,et al.  A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. , 2000, Molecular cell.

[390]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[391]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[392]  D. Richardson.  Role of ceruloplasmin and ascorbate in cellular iron release. , 1999, The Journal of laboratory and clinical medicine.

[393]  W. Jefferies,et al.  Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease , 1999, Brain Research.

[394]  P. Thong,et al.  Iron and cell death in Parkinson’s disease: a nuclear microscopic study into iron-rich granules in the parkinsonian substantia nigra of primate models , 1999 .

[395]  H. Koeffler,et al.  Molecular Cloning of Transferrin Receptor 2 , 1999, The Journal of Biological Chemistry.

[396]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[397]  D. Richardson,et al.  The effect of intracellular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake. , 1999, European journal of biochemistry.

[398]  J Kim,et al.  Copper(II)-induced self-oligomerization of alpha-synuclein. , 1999, The Biochemical journal.

[399]  Masashi Narita,et al.  Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC , 1999, Nature.

[400]  M. Bloom,et al.  Identification of a Cell Surface Protein from Crandell Feline Kidney Cells That Specifically Binds Aleutian Mink Disease Parvovirus , 1999, Journal of Virology.

[401]  Nancy Andrews,et al.  Transferrin receptor is necessary for development of erythrocytes and the nervous system , 1999, Nature Genetics.

[402]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[403]  K. Jellinger,et al.  The Role of Iron in Neurodegeneration , 1999, Drugs & aging.

[404]  Gregory J. Anderson,et al.  Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse , 1999, Nature Genetics.

[405]  E. Morgan,et al.  Evidence for low molecular weight, non‐transferrin‐bound iron in rat brain and cerebrospinal fluid , 1998, Journal of neuroscience research.

[406]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[407]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[408]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[409]  E. Morgan,et al.  Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency , 1998, The Journal of comparative neurology.

[410]  P. Ponka,et al.  Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism , 1998, American journal of hematology.

[411]  H. Payami,et al.  Genetic Epidemiology of Parkinson's Disease , 1998, Journal of geriatric psychiatry and neurology.

[412]  G. Bonvento,et al.  Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study , 1998, Glia.

[413]  S. Daniel,et al.  Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[414]  R. Eisenstein,et al.  Iron Differentially Stimulates Translation of Mitochondrial Aconitase and Ferritin mRNAs in Mammalian Cells , 1998, The Journal of Biological Chemistry.

[415]  N. Andrews,et al.  Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[416]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[417]  P. Fox,et al.  Role of ceruloplasmin in cellular iron uptake. , 1998, Science.

[418]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[419]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[420]  B. N. Patel,et al.  A Novel Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin Is Expressed by Mammalian Astrocytes* , 1997, The Journal of Biological Chemistry.

[421]  M. Bradbury.  Transport of Iron in the Blood‐Brain‐Cerebrospinal Fluid System , 1997, Journal of neurochemistry.

[422]  N. Andrews,et al.  Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene , 1997, Nature genetics.

[423]  Stephan Nussberger,et al.  Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.

[424]  B. Bergamasco,et al.  EPR investigations of the iron domain in neuromelanin. , 1997, Biochimica et biophysica acta.

[425]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[426]  R. Liddington,et al.  Raf-1 Kinase and Exoenzyme S Interact with 14-3-3ζ through a Common Site Involving Lysine 49* , 1997, The Journal of Biological Chemistry.

[427]  G. Cohen,et al.  Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[428]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.

[429]  P. Højrup,et al.  Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. , 1997, The Biochemical journal.

[430]  D. Richardson,et al.  Can ferritin provide iron for hemoglobin synthesis? , 1997, Blood.

[431]  D. Richardson,et al.  The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.

[432]  T. Taira,et al.  DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. , 1997, Biochemical and biophysical research communications.

[433]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[434]  T. Moos.  Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system , 1996, The Journal of comparative neurology.

[435]  H. Feldman,et al.  Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.

[436]  R. Broadwell,et al.  Transcytosis of Protein through the Mammalian Cerebral Epithelium and Endothelium III. Receptor-Mediated Transcytosis through the Blood–Brain Barrier of Blood-Borne Transferrin and Antibody against the Transferrin Receptor , 1996, Experimental Neurology.

[437]  K. Jellinger,et al.  Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. , 1996, Biochimica et biophysica acta.

[438]  P. Harrison,et al.  The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.

[439]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[440]  R D Klausner,et al.  Differences in the RNA binding sites of iron regulatory proteins and potential target diversity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[441]  D. Richardson,et al.  Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. , 1996, Blood.

[442]  L. Kühn,et al.  Iron Regulatory Proteins 1 and 2 Bind Distinct Sets of RNA Target Sequences (*) , 1996, The Journal of Biological Chemistry.

[443]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[444]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.

[445]  B. Deurs,et al.  A transferrin-like GPI-linked iron-binding protein in detergent- insoluble noncaveolar microdomains at the apical surface of fetal intestinal epithelial cells , 1995, The Journal of cell biology.

[446]  D. Richardson,et al.  The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. , 1995, Blood.

[447]  J. Phillips,et al.  Iron Regulates the Intracellular Degradation of Iron Regulatory Protein 2 by the Proteasome (*) , 1995, The Journal of Biological Chemistry.

[448]  P. Riederer,et al.  Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra , 1995, Journal of neurochemistry.

[449]  R. MacGillivray,et al.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[450]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.

[451]  Akinori Nakamura,et al.  A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans , 1995, Nature Genetics.

[452]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[453]  C. Morris,et al.  Iron histochemistry of the substantia nigra in Parkinson's disease. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[454]  D. Richardson,et al.  Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake , 1994, Journal of cellular physiology.

[455]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[456]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[457]  S. Heales,et al.  Effects of 1‐Methyl‐4‐Phenylpyridinium on Isolated Rat Brain Mitochondria: Evidence for a Primary Involvement of Energy Depletion , 1994, Journal of neurochemistry.

[458]  L. Kühn,et al.  Optimal sequence and structure of iron-responsive elements. Selection of RNA stem-loops with high affinity for iron regulatory factor. , 1994, The Journal of biological chemistry.

[459]  E. Rosengren,et al.  Neuromelanin of the Human Substantia Nigra: A Mixed‐Type Melanin , 1994, Journal of neurochemistry.

[460]  R. Ramsay,et al.  Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.

[461]  J. Cooper,et al.  Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.

[462]  M. Caron,et al.  Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[463]  R. Broadwell,et al.  Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain-blood barriers , 1993, Journal of neurocytology.

[464]  R. Klausner,et al.  Regulating the fate of mRNA: The control of cellular iron metabolism , 1993, Cell.

[465]  E. Morgan,et al.  Iron and transferrrin uptake by brain and cerebrospinal fluid in the rat , 1992, Brain Research.

[466]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[467]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[468]  T. S. St. Pierre,et al.  A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells. , 1992, Biochimica et biophysica acta.

[469]  D. Richardson,et al.  Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2‐hydroxy‐1‐naphthylaldehyde using the hepatocyte in culture , 1992, Hepatology.

[470]  H. Baker,et al.  Human melanotransferrin (p97) has only one functional iron‐binding site , 1992, FEBS letters.

[471]  E. Morgan,et al.  Transferrin and Iron Uptake by the Brain: Effects of Altered Iron Status , 1991, Journal of neurochemistry.

[472]  A. Vanin.  Endothelium‐derived relaxing factor is a nitrosyl iron complex with thiol ligands , 1991, FEBS letters.

[473]  J. Covès,et al.  Inactivation of ribonucleotide reductase by nitric oxide. , 1991, Biochemical and biophysical research communications.

[474]  T. Cox,et al.  Human erythroid 5‐aminolevulinate synthase: promoter analysis and identification of an iron‐responsive element in the mRNA. , 1991, The EMBO journal.

[475]  D. Richardson,et al.  The uptake of inorganic iron complexes by human melanoma cells. , 1991, Biochimica et biophysica acta.

[476]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[477]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[478]  B. Giometto,et al.  Transferrin receptors in rat central nervous system An immunocytochemical study , 1990, Journal of the Neurological Sciences.

[479]  C. Stout,et al.  Structure of activated aconitase: formation of the [4Fe-4S] cluster in the crystal. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[480]  D. Richardson,et al.  The uptake of iron and transferrin by the human malignant melanoma cell. , 1990, Biochimica et biophysica acta.

[481]  J. Langston,et al.  Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes , 1990, Journal of neurochemistry.

[482]  G. Brittenham.  Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. , 1990, Seminars in hematology.

[483]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[484]  J. Lancaster,et al.  EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[485]  J. Drapier,et al.  IFN-gamma-activated macrophages: detection by electron paramagnetic resonance of complexes between L-arginine-derived nitric oxide and non-heme iron proteins. , 1990, Biochemical and biophysical research communications.

[486]  Y. Hwang,et al.  Manganese induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. , 1989, British journal of industrial medicine.

[487]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[488]  M. Graeber,et al.  Increase of transferrin receptors and iron uptake in regenerating motor neurons , 1989, Journal of neuroscience research.

[489]  J. Connor,et al.  Do oligodendrocytes mediate iron regulation in the human brain? , 1989, Annals of neurology.

[490]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[491]  C H Ngim,et al.  Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. , 1989, Neuroepidemiology.

[492]  S. Hjorth,et al.  Synthesis and Release of Dopamine in Rat Brain: Comparison Between Substantia Nigra Pars Compacta, Pars Reticulata, and Striatum , 1989, Journal of neurochemistry.

[493]  P. Sadler,et al.  Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.

[494]  D. Richardson,et al.  Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. , 1988, Biochimica et biophysica acta.

[495]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[496]  Lukas C. Kühn,et al.  A stem-loop in the 3′ untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm , 1988, Cell.

[497]  R D Klausner,et al.  Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. , 1988, Science.

[498]  P. Riederer,et al.  Tyrosine Hydroxylase Activity in Caudate Nucleus from Parkinson's Disease: Effects of Iron and Phosphorylating Agents , 1988, Journal of neurochemistry.

[499]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[500]  N. Saunders,et al.  Cellular distribution of transferrin immunoreactivity in the developing rat brain , 1987, Neuroscience Letters.

[501]  B. Bloch,et al.  Transferrin gene expression in choroid plexus of the adult rat brain , 1987, Brain Research Bulletin.

[502]  J. Hibbs,et al.  Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.

[503]  B. Bregman,et al.  Immunocytochemical distribution of transferrin and its receptor in the developing chicken nervous system. , 1986, Brain research.

[504]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[505]  W. Nicklas,et al.  Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐Phenylpyridinium , 1986, Journal of neurochemistry.

[506]  J. Connor,et al.  The distribution of transferrin immunoreactivity in the rat central nervous system , 1986, Brain Research.

[507]  B. Bloch,et al.  Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[508]  C. Pert,et al.  Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[509]  I. Pastan,et al.  Kinetics of transit of transferrin and epidermal growth factor through clathrin-coated membranes , 1984, Cell.

[510]  W. Jefferies,et al.  Transferrin receptor on endothelium of brain capillaries , 1984, Nature.

[511]  J. Hibbs,et al.  Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. , 1984, Biochemical and biophysical research communications.

[512]  E. Gelfand,et al.  Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation , 1984 .

[513]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[514]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[515]  B. Iacopetta,et al.  The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. , 1983, The Journal of biological chemistry.

[516]  A. Ciechanover,et al.  pH and the recycling of transferrin during receptor-mediated endocytosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[517]  R. Klausner,et al.  Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[518]  R. Doolittle,et al.  Human melanoma-associated antigen p97 is structurally and functionally related to transferrin , 1982, Nature.

[519]  J. Glowinski,et al.  Dendritic release of dopamine in the substantia nigra , 1981, Nature.

[520]  P. Ponka,et al.  Biliary Iron Excretion in Rats following Pyridoxal Isonicotinoyl Hydrazone , 1980, British journal of haematology.

[521]  J. Brown,et al.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[522]  P. Ponka,et al.  Mobilization of iron from reticulocytes , 1979, FEBS letters.

[523]  I. Fidler,et al.  Depression of macrophages in mice drinking hyperchlorinated water , 1977, Nature.

[524]  A Jacobs,et al.  Low molecular weight intracellular iron transport compounds. , 1977, Blood.

[525]  H. Chapman,et al.  Macrophage tumor killing: influence of the local environment. , 1977, Science.

[526]  M Sarić,et al.  Occupational exposure to manganese. , 1977, British journal of industrial medicine.

[527]  J. D. Parkes,et al.  "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.

[528]  M. Schlabach,et al.  The reaction of ferric salts with transferrin. , 1973, The Journal of biological chemistry.

[529]  Owen Ca.  Effects of iron on copper metabolism and copper on iron metabolism in rats , 1973 .

[530]  A. Diosy.  Monoamine oxidase inhibitors , 1984 .

[531]  E. Frieden,et al.  The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. , 1971, The Journal of biological chemistry.

[532]  G. R. Lee,et al.  The role of ceruloplasmin in iron metabolism. , 1970, The Journal of clinical investigation.

[533]  T. Reese,et al.  JUNCTIONS BETWEEN INTIMATELY APPOSED CELL MEMBRANES IN THE VERTEBRATE BRAIN , 1969, The Journal of cell biology.

[534]  E. Frieden,et al.  The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. , 1966, The Journal of biological chemistry.

[535]  Preethi Philomina,et al.  Neuroferritinopathy , 2020 .

[536]  G. Töpfer.  Transferrin , 2019, Springer Reference Medizin.

[537]  Hana Jansová,et al.  Cardioprotective Potential of Iron Chelators and Prochelators. , 2019, Current medicinal chemistry.

[538]  L. Banci,et al.  Intracellular metal binding and redox behavior of human DJ-1 , 2017, JBIC Journal of Biological Inorganic Chemistry.

[539]  G. Di Trapani,et al.  The Multifaceted Roles of DJ-1 as an Antioxidant. , 2017, Advances in experimental medicine and biology.

[540]  M. Mouradian,et al.  Regulation of Signal Transduction by DJ-1. , 2017, Advances in experimental medicine and biology.

[541]  Christine Klein,et al.  Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[542]  K. Takata,et al.  Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7. , 2011, Journal of pharmacological sciences.

[543]  E. Rizzarelli,et al.  Neurodegeneration: Metallostasis and Proteostasis , 2011 .

[544]  B. Hyman,et al.  Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. , 2010, Biochemical and biophysical research communications.

[545]  D James Surmeier,et al.  What causes the death of dopaminergic neurons in Parkinson's disease? , 2010, Progress in brain research.

[546]  George Perry,et al.  Oxidative stress and neurotoxicity. , 2008, Chemical research in toxicology.

[547]  N. Andrews.  When is a heme transporter not a heme transporter? When it's a folate transporter. , 2007, Cell metabolism.

[548]  Hui Yang,et al.  Environmental toxins and α-synuclein in Parkinson’s disease , 2007, Molecular Neurobiology.

[549]  P. Buehler,et al.  CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. , 2006, Blood.

[550]  M. Núñez,et al.  Iron dyshomeostasis in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[551]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[552]  Nobutaka Hattori,et al.  Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. , 2005, Human molecular genetics.

[553]  T. Araki,et al.  Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[554]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[555]  P. Ponka,et al.  Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. , 2005, Blood.

[556]  J. Joseph,et al.  Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. , 2004, The Journal of biological chemistry.

[557]  T. Hastings,et al.  Could a loss of alpha-synuclein function put dopaminergic neurons at risk? , 2004, Journal of neurochemistry.

[558]  N. Weiner,et al.  Tyrosine hydroxylase regulation in the central nervous system , 2004, Molecular and Cellular Biochemistry.

[559]  D. D. Di Monte.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.

[560]  D. Richardson,et al.  Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[561]  M. Zigmond,et al.  A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[562]  James Parkinson,et al.  An essay on the shaking palsy. 1817. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[563]  B. Halliwell,et al.  Role of Free Radicals in the Neurodegenerative Diseases , 2001, Drugs & aging.

[564]  S. Paik,et al.  Structural changes in α‐synuclein affect its chaperone‐like activity in vitro , 2000, Protein science : a publication of the Protein Society.

[565]  P. Lansbury,et al.  Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. , 2000, Annals of the New York Academy of Sciences.

[566]  C. Beaumont,et al.  Function and regulation of transferrin and ferritin. , 1998, Seminars in hematology.

[567]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[568]  A. Vanin.  Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. , 1998, Biochemistry. Biokhimiia.

[569]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.

[570]  R. Fine,et al.  Development of transferrin‐positive oligodendrocytes in the rat central nervous system , 1987, Journal of neuroscience research.

[571]  E. Morgan,et al.  Transferrin, biochemistry, physiology and clinical significance , 1981 .

[572]  P. Reichard,et al.  Reduction of ribonucleotides. , 1979, Annual review of biochemistry.